Abstract 443P
Background
The low survival rate of cancer patients, especially patients who got metastases, necessitates an approach in providing additional therapy that is safe, capable of delaying disease progression, and prolonging patient survival. Vitamin D is an adjunctive therapy that is easy to obtain and shows anti-neoplastic activity against cancer so that it can reduce mortality. This study aimed to conduct a systematic review and meta-analysis regarding the efficacy of vitamin D supplementation in overall survival (OS) of cancer patients.
Methods
A systematic search of various databases up to end of 2022 was conducted to identify Randomized Controlled Trials (RCTs) involving the efficacy of vitamin D supplementation in OS of cancer patients. By using a random effect model, pooled hazard ratios (HR) with 95% confidence intervals (CI) were calculated to determine the values of OS. In formulating the study problem, we determine the study questions based on the study background, which consists of the populations (P), interventions (I), comparisons (C), and outcomes (O). The populations were cancer patients. The intervention was administration of vitamin D supplementation. The comparison was no administration of vitamin D supplementation. The outcome was OS. The RCTs having cancer patients over 18 years of age with available and sufficient information about OS were the inclusion criteria of this study. Study that has participants taking vitamin D supplementation regularly, and ongoing study with results not presented or published at the time of the literature search were the exclusion criteria of this study.
Results
Of the six RCTs, analysis was performed on 1,916 cancer patients in this study. In terms of survival, statistically, there was no difference in OS [HR 0.97, 95% CI 0.74 – 1.28, p = 0.85] between vitamin D supplementation and no supplementation in cancer patients.
Conclusions
Although vitamin D supplementation does not improve OS in cancer patients, is could be considered because it still shows benefits for cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Department of Internal Medicine, Faculty of Medicine, Sam Ratulangi University / Prof. dr. R. D. Kandou General Hospital, Manado, Indonesia.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
163P - Chemotherapy versus palliative radiotherapy in advanced inoperable gall bladder cancer
Presenter: Vimal Sekar
Session: Poster Display
Resources:
Abstract
164P - Neoadjuvant immune checkpoints inhibitors plus chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma
Presenter: Ming-Wei Kao
Session: Poster Display
Resources:
Abstract
165P - BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Elisabeth Amadeo
Session: Poster Display
Resources:
Abstract
166P - Preoperative risk factors strongly related to early recurrence after R0 resection of gallbladder cancer
Presenter: SANGHUN LEE
Session: Poster Display
Resources:
Abstract
167P - Peripheral blood neutrophil-to-lymphocyte ratio correlated with serum IL-8 level and predict the outcome of hepatocellular carcinoma patients treated with immune-targeted combination therapy
Presenter: Xuenan Peng
Session: Poster Display
Resources:
Abstract
168P - Real-world clinicopathological characteristics and treatment patterns of esophageal cancer patients in China
Presenter: Zhihao Lu
Session: Poster Display
Resources:
Abstract
169P - Conversion response and prognostic factors in HCC patients with macrovascular invasion treated with atezolizumab plus bevacizumab
Presenter: xiaodong Zhu
Session: Poster Display
Resources:
Abstract
170P - Atezolizumab plus bevacizumab (A+B) versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma (HCC): A large real-life worldwide population
Presenter: Francesco Vitiello
Session: Poster Display
Resources:
Abstract
171P - Retrospective study of the correlation between proteinuria and renal function in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with atezolizumab plus bevacizumab (Atezo+Bev): ARISE study
Presenter: Kazuomi Ueshima
Session: Poster Display
Resources:
Abstract
172P - Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial
Presenter: Zhi Peng
Session: Poster Display
Resources:
Abstract